Kyverna Therapeutics announces completion of bla submission for Miv-cel in Stiff Person Syndrome and reports third quarter 2026 financial re
Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first ap
Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first ap